Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service lumbar fusion cases in Texas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (239 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 184 | 8,136 | 44% |
| 2020 | 175 | 7,133 | 47% |
| 2021 | 192 | 8,058 | 51% |
| 2022 | 198 | 8,582 | 54% |
| 2023 | 195 | 8,116 | 57% |
| 2024 | 196 | 8,171 | 59% |
| 2025 from claims | – | 8,429 7,735–8,918 | 59% |
| 2026 forecast | – | 8,702 7,656–10,042 | 60% |
| 2027 forecast | – | 8,976 7,674–10,697 | 60% |
| 2028 forecast | – | 9,258 7,725–11,336 | 61% |
| 2029 forecast | – | 9,547 7,798–11,973 | 61% |
| 2030 forecast | – | 9,843 7,886–12,614 | 62% |
Posterolateral, interbody, and anterior lumbar fusion with instrumentation. Professional codes (what the surgeon bills): CPT 22612, 22630, 22633, 22558; the hospital bills MS-DRG 453, 454, 455, 459, 460, 402, 426, 427, 428, 447, 448, 450, 451, 523, 524, 525.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 17% of the cases CMS names in Texas; 112 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 83% inpatient hospital, 13% hospital outpatient, 4% surgery center. The share outside the hospital has moved +4 pts since 2019, so more of this market is decided in surgery centers and offices each year.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 165 | 7,337+0.8%/yr | +0.8%/yr | 3.2 | 7% | 9,130 in 2030+3.7%/yr |
| North Carolina | 81 | 3,107−4.5%/yr | −4.5%/yr | 3.0 | 0% | 3,140 in 2030+0.2%/yr |
| Georgia | 75 | 3,096−2.3%/yr | −2.3%/yr | 3.4 | 3% | 3,640 in 2030+2.7%/yr |
| Virginia | 72 | 3,069−1.3%/yr | −1.3%/yr | 2.9 | 0% | 3,830 in 2030+3.8%/yr |
| Tennessee | 71 | 2,726+1.2%/yr | +1.2%/yr | 3.7 | 0% | 3,030 in 2030+1.8%/yr |
| Maryland | 58 | 2,364−2.2%/yr | −2.2%/yr | 2.6 | 5% | 2,480 in 2030+0.8%/yr |
| South Carolina | 56 | 2,015−1.3%/yr | −1.3%/yr | 2.8 | 1% | 2,510 in 2030+3.8%/yr |
| Louisiana | 39 | 1,859+1.8%/yr | +1.8%/yr | 4.4 | 0% | 2,180 in 2030+2.7%/yr |
| Oklahoma | 45 | 1,762−4.7%/yr | −4.7%/yr | 3.5 | 1% | 1,970 in 2030+1.9%/yr |
| Alabama | 41 | 1,657−1.3%/yr | −1.3%/yr | 3.6 | 2% | 1,880 in 2030+2.1%/yr |
| Kentucky | 33 | 1,251−4%/yr | −4%/yr | 2.6 | 1% | 1,500 in 2030+3.1%/yr |
| Arkansas | 24 | 751−6.1%/yr | −6.1%/yr | 1.9 | 5% | 730 in 2030−0.5%/yr |
| Mississippi | 14 | 679−5.9%/yr | −5.9%/yr | 1.8 | 0% | 520 in 2030−4.5%/yr |
| Delaware | 12 | 599−2.6%/yr | −2.6%/yr | 3.4 | 10% | 670 in 2030+2%/yr |
| District of Columbia | 8 | 338+2.1%/yr | +2.1%/yr | 5.2 | 3% | 370 in 2030+1.6%/yr |
| West Virginia | 9 | 303−1.5%/yr | −1.5%/yr | 1.4 | 0% | 330 in 2030+1.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 195 | 8,404−6.2%/yr | −6.2%/yr | 3.81.2× | 4% | 9,180 in 2030+1.5%/yr |
| Cervical fusion & disc arthroplasty | 91 | 4,236−3.4%/yr | −3.4%/yr | 1.91.1× | 3% | 4,580 in 2030+1.3%/yr |
| Kyphoplasty & vertebroplasty | 43 | 3,866−5.3%/yr | −5.3%/yr | 1.81.0× | 26% | 3,550 in 2030−1.4%/yr |
| SI joint fusion | 20 | 1,201+17%/yr | +17%/yr | 0.51.7× | 59% | 2,330 in 2030+12%/yr |
Lumbar fusion in every state, and its device makers · Every procedure market in Texas · Every state · Compare with Florida
Medtronic leads with 28% of company spending on these surgeons in 2025, −2 pts on 2024.
In 2025, 35 companies reported engagement with Texas’s surgeons worth $1.8M in consulting, speaking, meals and travel tied to these products, about $8,993 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 87 clearances and approvals in the category, 12 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.